NEW YORK--(BUSINESS WIRE)--
Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering
consisting of four tranches of notes:
€1,250,000,000 aggregate principal amount of floating rate notes due 2019
€1,000,000,000 aggregate principal amount of 0.000% notes due 2020
€1,000,000,000 aggregate principal amount of 0.250% notes due 2022
€750,000,000 aggregate principal amount of 1.000% notes due 2027
Interest on the floating rate notes will be three month EURIBOR plus
0.20%, reset quarterly. Pfizer intends to use the net offering proceeds
for general corporate purposes, including to repay a portion of its
outstanding commercial paper.
Pfizer intends to apply to list the notes on the New York Stock
Exchange. The closing of the offering is expected to occur on March 6,
2017, subject to satisfaction of customary closing conditions.
Barclays Bank PLC, BNP Paribas, Goldman, Sachs & Co. and J.P. Morgan
Securities plc are acting as joint book-running managers for the
offering.
The offering of these securities is being made only by means of a
prospectus. Copies may be obtained by calling Barclays Bank PLC at +44
20 7773 9098, BNP Paribas at 1-800-854-5674, Goldman, Sachs & Co. at
1-866-471-2526 or J.P. Morgan Securities plc at +44 20 7134 2468.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the notes, nor will there be any
sale of the notes in any jurisdiction in which such offer, solicitation,
or sale would be unlawful.
Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world's
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world's
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer
and @PfizerNews,
LinkedIn,
YouTube
and like us on Facebook at Facebook.com/Pfizer.
Forward-Looking Statements
This press release contains forward-looking statements made within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements involve substantial risks and uncertainties.
We have tried, wherever possible, to identify such statements by using
words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,”
“forecast,” “goal,” “objective,” “aim” and other words and terms of
similar meaning or by using future dates in connection with any
discussion of, among other things, expectations regarding the completion
of the notes offering and the use of proceeds. A list and description of
risks, uncertainties and other matters can be found in our Annual Report
on Form 10-K for the year ended December 31, 2016, including in the
sections thereof captioned “Forward-Looking Information and Factors That
May Affect Future Results” and “Risk Factors,” in our Quarterly Reports
on Form 10-Q, in our Current Reports on Form 8-K, and in the prospectus
supplement and accompanying prospectus, in each case including in the
section thereof captioned “Risk Factors.” You should understand that it
is not possible to predict or identify all such factors. Consequently,
you should not consider any such list to be a complete set of all
potential risks or uncertainties.
We cannot guarantee that any forward-looking statement will be
realized, although we believe we have been prudent in our plans and
assumptions. Achievement of anticipated results is subject to
substantial risks, uncertainties and inaccurate assumptions. Should
known or unknown risks or uncertainties materialize, or should
underlying assumptions prove inaccurate, actual results could vary
materially from past results and those anticipated, estimated or
projected. You should bear this in mind as you consider forward-looking
statements, and you are cautioned not to put undue reliance on
forward-looking statements. We undertake no obligation to publicly
update forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law or by
the rules and regulations of the Securities and Exchange Commission (the
“SEC”). You are advised, however, to consult any further disclosures we
make on related subjects in our reports on Form 10-K, 10-Q and 8-K and
our other filings with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170228006949/en/
Source: Pfizer Inc.